Discovery of Thienoimidazole-Based HCV NS5A Genotype 1a and 1b Inhibitors

Simon Giroux, Jinwang Xu, T. Jagadeeswar Reddy, Mark R. Morris, Kevin M. Cottrell, Caroline Cadilhac, James A. Henderson, O. Nicolas, Darius Bilimoria, François Denis,

ACS Medicinal Chemistry Letters · 2013 · 14 citations · 6 references

Concepts

Abstract

The discovery of potent thienoimidazole-based HCV NS5A inhibitors is herein reported. A novel method to access the thienoimidazole [5,5]-bicyclic system is disclosed. This method gave access to a common key intermediate (6) that was engaged in Suzuki or Sonogashira reactions with coupling partners bearing different linkers. A detailed study of the structure-activity relationship (SAR) of the linkers revealed that aromatic linkers with linear topologies are required to achieve high potency for both 1a and 1b HCV genotypes. Compound 20, with a para-phenyl linker, was identified as a potential lead displaying potencies of 17 and 8 pM against genotype 1a and 1b replicons, respectively.

References

6